181 related articles for article (PubMed ID: 17848947)
1. [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.
Suttie SA; Park KG; Smith TA
Br J Cancer; 2007 Oct; 97(7):902-9. PubMed ID: 17848947
[TBL] [Abstract][Full Text] [Related]
2. Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
Sharma RI; Smith TA
J Nucl Med; 2008 Aug; 49(8):1386-94. PubMed ID: 18632807
[TBL] [Abstract][Full Text] [Related]
3. Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling.
Cooper AC; Fleming IN; Phyu SM; Smith TA
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1523-32. PubMed ID: 25579456
[TBL] [Abstract][Full Text] [Related]
4. Decreased [18F]fluoro-2-deoxy-d-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro.
Smith TA; Sharma RI; Wang WG; Welch AE; Schweiger LF; Collie-Duguid ES
Nucl Med Biol; 2007 Nov; 34(8):955-60. PubMed ID: 17998098
[TBL] [Abstract][Full Text] [Related]
5. Early changes in [18F]FLT uptake after chemotherapy: an experimental study.
Dittmann H; Dohmen BM; Kehlbach R; Bartusek G; Pritzkow M; Sarbia M; Bares R
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1462-9. PubMed ID: 12397465
[TBL] [Abstract][Full Text] [Related]
6. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
Eatock MM; Anthony DA; El-Abassi M; Wilson P; Paul J; Smith M; Soukop M; Evans TR
Br J Cancer; 2000 Jun; 82(12):1925-31. PubMed ID: 10864199
[TBL] [Abstract][Full Text] [Related]
7. Intermittent continuous infusion of 5-fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity.
Poorter RL; Bakker PJ; Fockens P; Taat CW; Bartelsman JF; Veenhof CH
J Infus Chemother; 1996; 6(2):87-91. PubMed ID: 8809656
[TBL] [Abstract][Full Text] [Related]
8. Influence of resistance to 5-fluorouracil and tomudex on [18F]‑FDG incorporation, glucose transport and hexokinase activity.
Law AA; Collie-Duguid ES; Smith TA
Int J Oncol; 2012 Jul; 41(1):378-82. PubMed ID: 22576694
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer.
Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV
J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
Strickland AH; Karapetis CS; Yip D; Harper PG
Clin Oncol (R Coll Radiol); 2001; 13(1):66. PubMed ID: 11292143
[No Abstract] [Full Text] [Related]
11. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer.
Couper GW; McAteer D; Wallis F; Norton M; Welch A; Nicolson M; Park KG
Br J Surg; 1998 Oct; 85(10):1403-6. PubMed ID: 9782025
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma.
Highley MS; Parnis FX; Trotter GA; Houston SJ; Penson RT; Harper PG; Mason RC
Br J Surg; 1994 Dec; 81(12):1763-5. PubMed ID: 7530150
[TBL] [Abstract][Full Text] [Related]
13. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Dose-Schwarz J; Tiling R; Avril-Sassen S; Mahner S; Lebeau A; Weber C; Schwaiger M; Jänicke F; Untch M; Avril N
Br J Cancer; 2010 Jan; 102(1):35-41. PubMed ID: 19920815
[TBL] [Abstract][Full Text] [Related]
14. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial.
Ott K; Fink U; Becker K; Stahl A; Dittler HJ; Busch R; Stein H; Lordick F; Link T; Schwaiger M; Siewert JR; Weber WA
J Clin Oncol; 2003 Dec; 21(24):4604-10. PubMed ID: 14673049
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Thuss-Patience PC; Kretzschmar A; Repp M; Kingreen D; Hennesser D; Micheel S; Pink D; Scholz C; Dörken B; Reichardt P
J Clin Oncol; 2005 Jan; 23(3):494-501. PubMed ID: 15659494
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer.
Yao Z; Guo H; Yuan Y; Zhao Y; Yao S; Xu Y; Liu L; Liu T; Liu Y; Yang S
J Chemother; 2014 Apr; 26(2):117-21. PubMed ID: 24090813
[TBL] [Abstract][Full Text] [Related]
17. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
18. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting.
Kilickap S; Yalcin S; Ates O; Tekuzman G
Hepatogastroenterology; 2011; 58(105):208-12. PubMed ID: 21510316
[TBL] [Abstract][Full Text] [Related]
19. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
Woo IS; Moon DH; Shim BY; Lee MA; Byun JH; Kim KW; Kang JH; Choi MG; Chung IS; Hong YS; Park SY; Lee KS
Jpn J Clin Oncol; 2005 Jan; 35(1):13-7. PubMed ID: 15681598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]